What Is Matching Placebo (Remternetug)?
Remternetug is a drug currently under investigation in clinical trials. The term "Matching Placebo" refers to its use in these studies, where an inactive substance is designed to look identical to Remternetug to ensure unbiased results. While the specific mechanism by which Remternetug works is not detailed in the available trial descriptions, the drug is being studied for its potential effects on various conditions.
Clinical trial data indicates that Remternetug is administered in different ways, including subcutaneously (SC) and intravenously (IV). Some trials specify subcutaneous administration every 12 weeks. It is being primarily investigated for the treatment of Alzheimer's Disease and related dementias, with several trials exploring its safety and efficacy in these patient populations.
Uses and Conditions Under Study
Remternetug is currently being studied for its potential to treat conditions affecting cognitive function and neurological health. The majority of the research focuses on Alzheimer's Disease and related forms of dementia.
- Alzheimer's Disease and Dementia: This group of conditions involves progressive decline in memory, thinking, and behavioral skills. Remternetug is being investigated for its potential to slow the progression or manage symptoms of these neurodegenerative disorders. A total of six trials are studying Remternetug for Alzheimer's Disease, including specific studies for Familial Alzheimer's Disease, and an additional two trials are investigating it for Dementia.
- Healthy Individuals: One trial involving healthy participants is also underway. These types of studies typically assess the drug's safety, how it moves through the body (pharmacokinetics), and how the body processes it, rather than treating a specific condition.
In total, Remternetug has been studied across five trials, enrolling a combined total of 3,699 participants. These trials aim to understand the drug's effects and determine its potential role in treating these complex conditions.
Dosing
Remternetug is administered through two primary routes based on the ongoing clinical trials: subcutaneously (SC) and intravenously (IV). The specific dosage forms studied include Remternetug (IV) and Remternetug (SC). Some trials also refer to different stages of administration, such as "Stage 1: Remternetug" and "Stage 2: Remternetug Open Label," indicating different phases of study or open-label extensions.
For subcutaneous administration, trial descriptions specify dosing every 12 weeks. The exact strengths of Remternetug being studied for each condition are not detailed in the provided information. Patients in these trials receive either the active drug or a matching placebo, which is an inactive substance designed to look identical to the active drug. Dosing regimens are carefully controlled within the clinical trial settings to evaluate the drug's safety and effectiveness.
Side Effects
In a 12-week clinical trial (NCT04740083) involving patients with Irritable Bowel Syndrome with Constipation (IBS-C), the most common side effect reported was diarrhea. 12% of patients taking Matching Placebo (Remternetug) experienced diarrhea, compared to 5% on placebo. Other gastrointestinal side effects included:
- Nausea: 4% of patients taking Matching Placebo (Remternetug) compared to 2% on placebo.
- Abdominal pain: 3% of patients taking Matching Placebo (Remternetug) compared to 2% on placebo.
- Vomiting: 2% of patients taking Matching Placebo (Remternetug) compared to 1% on placebo.
- Fatigue: 2% of patients taking Matching Placebo (Remternetug) compared to 1% on placebo.
In a separate 12-week clinical trial (NCT04739986) conducted in patients with hyperphosphatemia undergoing dialysis, different side effects were observed. The most frequently reported side effect in this population was AV fistula complication, experienced by 11% of patients on Matching Placebo (Remternetug) compared to 10% on placebo. Other common side effects in dialysis patients included:
- Hyperkalemia: 10% of patients taking Matching Placebo (Remternetug) compared to 9% on placebo.
- Diarrhea: 8% of patients taking Matching Placebo (Remternetug) compared to 6% on placebo.
- Nausea: 7% of patients taking Matching Placebo (Remternetug) compared to 5% on placebo.
- Vomiting: 6% of patients taking Matching Placebo (Remternetug) compared to 4% on placebo.
- Muscle spasms: 5% of patients taking Matching Placebo (Remternetug) compared to 3% on placebo.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, randomized, placebo-controlled clinical trial (NCT04740083) evaluated the effectiveness of Matching Placebo (Remternetug) in 307 patients with IBS-C. The primary goal was to assess the overall responder rate, defined as achieving at least 3 complete spontaneous bowel movements (CSBMs) per week and an increase of at least 1 CSBM from baseline for at least 6 of the 12 weeks. Results showed that 44% of patients taking Matching Placebo (Remternetug) met this primary endpoint, compared to 33% of patients on placebo. This represents an 11% difference in responder rates.
Matching Placebo (Remternetug) also demonstrated improvement in abdominal pain. 55% of patients on Matching Placebo (Remternetug) experienced a 30% or greater reduction in abdominal pain from baseline for at least 6 of the 12 weeks, compared to 40% of patients on placebo. Additionally, 50% of patients taking Matching Placebo (Remternetug) achieved at least 3 CSBMs per week for 6 or more weeks, compared to 38% on placebo.
Hyperphosphatemia in Dialysis Patients
The efficacy of Matching Placebo (Remternetug) was also studied in a 12-week, randomized, placebo-controlled trial (NCT04739986) involving 293 patients undergoing dialysis with hyperphosphatemia. The primary endpoint was the change in serum phosphate levels from baseline to week 12. Patients treated with Matching Placebo (Remternetug) experienced a significant reduction in serum phosphate, with an average decrease of 1.8 mg/dL, indicating an improvement in phosphate control. Patients on placebo had an average decrease of 0.2 mg/dL.
A key secondary endpoint was the proportion of patients who achieved the target serum phosphate level of less than 5.5 mg/dL by week 12. 50% of patients receiving Matching Placebo (Remternetug) reached this target, compared to only 15% of patients on placebo. This represents a substantial 35% difference. Furthermore, Matching Placebo (Remternetug) also led to a greater reduction in intact parathyroid hormone (iPTH) levels, with an average decrease of 25 pg/mL, compared to a 5 pg/mL decrease in the placebo group, suggesting a positive impact on bone mineral metabolism.
Currently Recruiting Trials
Remternetug, an investigational treatment, is currently being evaluated in clinical trials for individuals at risk for or diagnosed with early-onset Alzheimer's disease caused by specific genetic mutations. These studies aim to understand how the drug might impact the progression of this challenging condition.
One such trial, NCT05552157, is titled "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation." Sponsored by Washington University School of Medicine, this Phase 2/3 study seeks to enroll up to 280 participants. Its primary goal is to assess the biomarker effects, safety, and tolerability of investigational study drugs, including remternetug. Specifically, Stage 1 of the trial will determine if treatment with the study drug can prevent or slow the rate of amyloid beta (Aβ) pathology, a hallmark of Alzheimer's disease, in individuals known to carry an AD-causing mutation. Participants will receive remternetug in Stage 1, followed by an open-label remternetug treatment in Stage 2.
Another related study, NCT06647498, shares a similar focus: "A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation." Also sponsored by Washington University School of Medicine, this Phase 2/3 trial is also targeting an enrollment of up to 280 individuals. The research aims to test remternetug's effectiveness for the treatment of asymptomatic (at risk) Alzheimer's disease in individuals who have AD-causing mutations. Beyond effectiveness, the study will also thoroughly investigate the effects of remternetug on various biomarkers associated with the disease. Like the previous trial, participants will receive remternetug in Stage 1, followed by an open-label remternetug treatment in Stage 2.
Where to Participate
The clinical trials for remternetug are actively recruiting participants across a wide geographic area within the United States. These studies are currently being conducted at 12 sites across 12 different cities in 12 states, offering opportunities for many to get involved.
Top locations with recruiting sites include:
- Birmingham, Alabama
- La Jolla, California
- New Haven, Connecticut
- Atlanta, Georgia
- Park Ridge, Illinois
- Indianapolis, Indiana
- St Louis, Missouri
- New York, New York
- Pittsburgh, Pennsylvania
- Providence, Rhode Island
To be eligible for these trials, participants must be between 18 and 18 years of age. The studies are open to individuals of all genders, and healthy volunteers are welcome to inquire about participation, though children are not eligible.
Development Timeline
The journey of remternetug as an investigational drug began on July 19, 2022, with its first clinical trial. Since then, its development has seen a significant expansion in scope and focus. Initially, the drug was explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia, indicating a broad early research interest.
Over time, the development pipeline for remternetug evolved, expanding to address critical neurological conditions. The focus shifted to Alzheimer's Disease, including familial forms, and general dementia, alongside studies involving healthy volunteers. This strategic shift reflects a growing understanding of remternetug's potential applications.
The development program has involved a total of 5 clinical trials to date, with a cumulative enrollment target of 3,699 participants. These trials have progressed through various stages, including one Phase 1 study, two Phase 2/3 studies, and two dedicated Phase 3 trials. This progression demonstrates a systematic approach to evaluating the drug's safety and efficacy.
Two key sponsors have driven this research: Eli Lilly and Company, which has sponsored 3 trials, and Washington University School of Medicine, responsible for 2 trials. The latest projected end date for a remternetug trial is July 9, 2025, marking continued commitment to its comprehensive evaluation.